The OJC 52: Do Steroids Matter? + No-Go, Slow-Go, Go-Go + Essential Medicines Access

Pinterest LinkedIn Tumblr +

The Oncology Journal Club Episode 52: Do Steroids Matter? + No-Go, Slow-Go, Go-Go + Essential Medicines Access

Welcome to this week’s episode of The OJC.

Join Eva Segelov, Craig Underhill and Hans Prenen as they chat through the latest papers. This week they discuss No-Go, Slow-Go, Go-Go, Essential Medicines Access. And they ask Do Steroids Matter?

Quick bites are diverse as ever covering Doctors’ strikes in Nigeria, Sex and Toxicity in Colorectal Cancer and much more.

You’ll also find out why you should never feel sorry for Hans again despite the fact that he wants a colonoscopy for his birthday!

Drop us a line on Twitter with any comments @oncologynewsaus

This Week’s Papers:

  1. Fundytus A, et al. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol. 2021 Oct;22(10):1367-1377. doi: 10.1016/S1470-2045(21)00463-0. Epub 2021 Sep 21. PMID: 34560006; PMCID: PMC8476341. Access online here.
  2. Lansinger OM, et al. Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions. J Clin Oncol. 2021 Aug 6:JCO2101200. doi: 10.1200/JCO.21.01200. Epub ahead of print. PMID: 34357780. Access online here.
  3. Itzykson RA, et al. Genetic Identification of AML Patients Older than 60 years Achieving Long-term Survival with Intensive Chemotherapy. Blood. 2021 May 27:blood.2021011103. doi: 10.1182/blood.2021011103. Epub ahead of print. PMID: 34046677. Access online here.


This Week’s Quick Bites:

  1. Ocak, Sebahat et al. Lung Cancer in Belgium. Journal of Thoracic Oncology, Volume 16, Issue 10, 1610 – 1621. Access online here.
  2. Das M. Cancer care crisis in Nigeria amid doctors’ strike. Lancet Oncol. 2021 Sep 23:S1470-2045(21)00569-6. doi: 10.1016/S1470-2045(21)00569-6. Epub ahead of print. PMID: 34563313. Access online here.
  3. Inker LA, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021 Sep 23. doi: 10.1056/NEJMoa2102953. Epub ahead of print. PMID: 34554658. Access online here.
  4. Lee, J.K. et al. Rising Early-Onset Colorectal Cancer Incidence is Not an Artifact of Increased Screening Colonoscopy Use in a Large, Diverse Healthcare System. Gastroenterology. Pub Date : 2021-09-20, DOI: 10.1053/j.gastro.2021.09.034 
  5. Jin Z, et al. Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. J Natl Cancer Inst. 2021 Aug 18:djab123. doi: 10.1093/jnci/djab123. Epub ahead of print. PMID: 34405233. Access online here.
  6. Cercek A, et al. A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. J Natl Cancer Inst. 2021 Aug 18:djab124. doi: 10.1093/jnci/djab124. Epub ahead of print. PMID: 34405229. Access online here.
  7. Vandeputte C, et al. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clin Colorectal Cancer. 2021 Jul 24:S1533-0028(21)00071-2. doi: 10.1016/j.clcc.2021.07.006. Epub ahead of print. PMID: 34404621. Access online here.
  8. van Velzen MJM, et al. The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer. Eur J Cancer. 2021 Oct;156:60-69. doi: 10.1016/j.ejca.2021.07.026. Epub 2021 Aug 20. PMID: 34425405. Access online here.
  9. Locati LD, et al.  Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. J Clin Oncol. 2021 Oct 1:JCO2100468. doi: 10.1200/JCO.21.00468. Epub ahead of print. PMID: 34597119. Access online here.
  10. Devarakonda S, et al. Genomic Profiling of Lung Adenocarcinoma in Never-Smokers. J Clin Oncol. 2021 Sep 30:JCO2101691. doi: 10.1200/JCO.21.01691. Epub ahead of print. PMID: 34591593. Access online here.
  11. Andre, T. et al. Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study. Journal of Clinical Oncology 2021 39:3_suppl, 9-9. Access online here.

Other Resources Mentioned:

eviQ: Cancer Treatments Online

Amazing Article of the Week:

Jennifer Rankin. ‘Better ugly than boring’: book celebrates bizarre Belgian houses’ The Guardian. Fri 24 Sep 2021. Access online here.

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

You can find Eva on Twitter here: @profevasegelov

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

You can find Hans on Twitter here: @HPrenen

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

You can find Craig on Twitter here: @CraigUnderhill 

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen and Graham Knowles.

Connect with us on Twitter @OncologyNewsAus


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.